Payment overview · 2025
General Payments
$163,756.56
248 reported records · 20 companies
Healthcare provider profile · identity verified
Nayan K Desai, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · BISMARCK, ND · NPI 1316368236
Verified facts
What the public records show
CMS Open Payments records show Nayan K Desai, MD received $163,756.56 in general payments during 2025 across 248 reported records.
Alnylam Pharmaceuticals Inc. accounted for 26.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Opsumit, Vyndamax.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPSUMIT as an associated drug or biological on 18955 records involving 8899 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Opsumit by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 462 claims for Eliquis by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Xarelto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 462 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYNDAMAX as an associated drug or biological on 1880 records involving 1527 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Vyndamax by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $43,329.12 | 26.5% | 37 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $31,215.49 | 19.1% | 49 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $29,022.22 | 17.7% | 20 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $20,540.47 | 12.5% | 20 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $15,369.44 | 9.4% | 31 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $10,613.37 | 6.5% | 19 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $5,806.29 | 3.5% | 26 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $4,616.61 | 2.8% | 8 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$2,416.38 | 1.5% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $206.21 | 0.1% | 6 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $179.05 | 0.1% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $105.81 | 0.1% | 6 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $100.14 | 0.1% | 2 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $72.66 | 0.0% | 3 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $51.88 | 0.0% | 2 | 2025 |
| LeMaitre Vascular, Inc. | Unresolved — no canonical attribution shown | $32.49 | 0.0% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $25.64 | 0.0% | 2 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $22.03 | 0.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.47 | 0.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.79 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $100,874.23 | 39 |
| Consulting Fee | $50,399.00 | 19 |
| Travel and Lodging | $8,842.15 | 26 |
| Food and Beverage | $3,542.18 | 163 |
| Education | $99.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $39,954.12 | 36 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $31,215.49 | 49 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc., Janssen Pharmaceuticals, Inc | $31,130.58 | 46 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $28,017.41 | 17 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $20,540.47 | 20 | 2025 |
Source payment records
|
|||||
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $13,309.73 | 11 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $9,788.12 | 16 | 2025 |
Source payment records
|
|||||
| ROTAPRO Normalized: rotapro |
Device | Boston Scientific Corporation | $5,625.00 | 2 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $4,596.41 | 7 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $2,397.26 | 4 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $2,131.91 | 6 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $625.00 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $317.21 | 18 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $179.05 | 7 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK CORONARY Normalized: diamondback coronary |
Device | Abbott Laboratories | $151.63 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $105.81 | 6 | 2025 |
Source payment records
|
|||||
| VersaCross Access Solution Normalized: versacross access solution |
Device | Boston Scientific Corporation | $87.37 | 13 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $43.51 | 2 | 2025 |
Source payment records
|
|||||
| Rotablator Rotational Atherectomy System Console Kit Normalized: rotablator rotational atherectomy system console kit |
Device | Boston Scientific Corporation | $32.97 | 3 | 2025 |
Source payment records
|
|||||
| HYDRO LEMAITRE VALVULOTOME Normalized: hydro lemaitre valvulotome |
Device | LeMaitre Vascular, Inc. | $32.49 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $26.37 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $26.37 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $25.51 | 1 | 2025 |
Source payment records
|
|||||
| MINI TREK Normalized: mini trek |
Device | Abbott Laboratories | $23.35 | 1 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $23.34 | 2 | 2025 |
Source payment records
|
|||||
| GORE CARDIOFORM ASD Occluder Normalized: gore cardioform asd occluder |
Device | W. L. Gore & Associates, Inc. | $22.03 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $17.40 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $13.79 | 1 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $13.50 | 1 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK PERIPHERAL Normalized: diamondback peripheral |
Device | Abbott Laboratories | $12.20 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Normalized: watchman |
Device | Boston Scientific Corporation | $11.82 | 2 | 2025 |
Source payment records
|
|||||
| MVP Normalized: mvp |
Device | Medtronic, Inc. | $9.94 | 1 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $9.18 | 1 | 2025 |
Source payment records
|
|||||
| General - Catheter Normalized: general catheter |
Device | Boston Scientific Corporation | $8.39 | 1 | 2025 |
Source payment records
|
|||||
| COROFLOW Normalized: coroflow |
Device | Abbott Laboratories | $5.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 462 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 96 | exact normalized | Medicare Part D |
| OPSUMIT opsumit |
2025 | Opsumit | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VYNDAMAX vyndamax |
2025 | Vyndamax | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | OPSUMIT open payments reported associated product |
CMS Open Payments — General Payments 18955 supporting records · 8899 recipient NPIs · example record 1174163978 |
Opsumit · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
96 | 20 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
462 | 109 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
162 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
462 | 109 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | VYNDAMAX open payments reported associated product |
CMS Open Payments — General Payments 1880 supporting records · 1527 recipient NPIs · example record 1228795749 |
Vyndamax · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 808 | 303 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 504 | 186 |
| Eliquis | Apixaban | 462 | 109 |
| Atorvastatin Calcium | Atorvastatin Calcium | 451 | 163 |
| Clopidogrel | Clopidogrel Bisulfate | 360 | 140 |
| Furosemide | Furosemide | 350 | 136 |
| Losartan Potassium | Losartan Potassium | 290 | 116 |
| Spironolactone | Spironolactone | 264 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 245 | 95 |
| Carvedilol | Carvedilol | 202 | 74 |
| Jardiance | Empagliflozin | 168 | 49 |
| Torsemide | Torsemide | 164 | 52 |
| Xarelto | Rivaroxaban | 162 | 43 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 149 | 63 |
| Lisinopril | Lisinopril | 148 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 137 | 49 |
| Amiodarone Hcl | Amiodarone Hcl | 109 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 103 | 41 |
| Mounjaro | Tirzepatide | 97 | 20 |
| Farxiga | Dapagliflozin Propanediol | 96 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 88 | 33 |
| Ezetimibe | Ezetimibe | 88 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 86 | 36 |
| Potassium Chloride | Potassium Chloride | 84 | 33 |
| Entresto | Sacubitril/Valsartan | 83 | 16 |
| Warfarin Sodium | Warfarin Sodium | 77 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 31 |
| Repatha Sureclick | Evolocumab | 65 | 12 |
| Bumetanide | Bumetanide | 64 | 25 |
| Nitroglycerin | Nitroglycerin | 59 | 41 |
| Digoxin | Digoxin | 52 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 52 | 19 |
| Flecainide Acetate | Flecainide Acetate | 51 | 20 |
| Midodrine Hcl | Midodrine Hcl | 47 | 21 |
| Jantoven | Warfarin Sodium | 45 | 12 |
| Opsumit | Macitentan | 43 | suppressed |
| Brilinta | Ticagrelor | 42 | suppressed |
| Simvastatin | Simvastatin | 42 | 17 |
| Metolazone | Metolazone | 39 | 20 |
| Praluent Pen | Alirocumab | 36 | suppressed |
| Chlorthalidone | Chlorthalidone | 35 | 11 |
| Atenolol | Atenolol | 34 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | 13 |
| Ranolazine Er | Ranolazine | 33 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 12 |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 24 | 17 |
| Vyndamax | Tafamidis | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Repatha Syringe | Evolocumab | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Eplerenone | Eplerenone | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Verapamil Sr | Verapamil Hcl | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Metformin Hcl | Metformin Hcl | 12 | suppressed |
| Orenitram Er | Treprostinil Diolamine | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $163,756.56 · 248 records | Alnylam Pharmaceuticals Inc. | AMVUTTRA, AVVIGO Guidance System, Attruby, CAMZYOS, COREVALVE EVOLUT R, COROFLOW, CT THROMBECTOMY SYSTEM KIT, DIAMONDBACK CORONARY, DIAMONDBACK PERIPHERAL, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), ELIQUIS, ESPRIT, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, FARXIGA, FLOWTRIEVER, FLOWTRIEVER CATHETER, S, GORE CARDIOFORM ASD Occluder, General - Catheter, HAWKONE, HYDRO LEMAITRE VALVULOTOME, Kerendia, MINI TREK, MVP, OPSUMIT, REPATHA, ROTAPRO, Rotablator Rotational Atherectomy System Console Kit, SAPIEN 3 Ultra RESILIA, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, Tyvaso, UPTRAVI, VERQUVO, VYNDAMAX, VYNDAQEL, VersaCross Access Solution, WAINUA, WATCHMAN, WATCHMAN FLX | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Actelion Pharmaceuticals US, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error